JCJuniel Assis Crespo-Neto

Juniel Assis Crespo-Neto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juniel Assis Crespo-Neto has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    HLA‐G in Hematological Malignancies: Immunoregulatory Mechanisms and Implications for Immune Evasion and Immunotherapy

    by Thaís Lohana Chanel Pereira Ribeiro, Glenda Menezes Nogueira, Mateus Souza-Barros, Júlia Santos Moraes, Larissa Silva Santos, Lucas Silva Oliveira, Juniel Assis Crespo-Neto, Julia Goes Souza Ghedini, Fábio Magalhães-Gama, Adriana Malheiro, et al.

    Human leukocyte antigen G (HLA‐G) is a nonclassical major histocompatibility complex class I molecule whose increased expression has been consistently associated with unfavorable prognosis in solid tumors and has emerged as a potential immunotherapeutic target in hematological malignancies. HLA‐G exhibits limited genetic diversity and generates multiple isoforms that play a critical role in immune tolerance, being physiologically expressed in immunoprivileged tissues and aberrantly upregulated in a variety of pathological conditions, including cancer. Accumulating evidence indicates that elevated HLA‐G expression contributes to tumor immune evasion and influences clinical outcomes in patients with leukemia, lymphoma, and multiple myeloma. Genetic variability within the HLA‐G gene, particularly polymorphisms located in regulatory regions such as the 14‐base pair insertion/deletion, has been associated with cancer susceptibility, disease progression, and adverse prognosis. In hematological malignancies, specific genotypes, including the homozygous deletion variant, have been linked to increased levels of membrane‐bound and soluble HLA‐G, correlating with impaired immune surveillance and reduced survival, particularly in chronic lymphocytic leukemia. Moreover, HLA‐G expressions may be modulated by inflammatory cytokines, such as interferon‐γ, further shaping the immunosuppressive tumor microenvironment. By functioning as a nonclassical immune checkpoint, HLA‐G represents a promising target for innovative immunotherapeutic strategies, including immune checkpoint blockade combinations and chimeric antigen receptor (CAR)‐T cell approaches directed against HLA‐G‐expressing malignant cells. In this review, we summarize current knowledge regarding HLA‐G expression, genetic polymorphisms, and immunoregulatory mechanisms in hematological malignancies, highlighting their clinical and translational implications. Improved understanding of HLA‐G‐mediated immune modulation may contribute to the development of novel prognostic biomarkers and therapeutic strategies aimed at restoring effective antitumor immunity.

  • Open Access

    Insights Regarding the Role of Inflammasomes in Leukemia: What Do We Know?

    by Fabíola Silva Alves-Hanna, Juniel Assis Crespo-Neto, Glenda Menezes Nogueira, Daniele Sá Pereira, Amanda Barros Lima, Thaís Lohana Pereira Ribeiro, Vitória Giovanna Rodrigues Santos, Joey Ramone Ferreira Fonseca, Fábio Magalhães-Gama, Aya Sadahiro, et al.

    Inflammation is a physiological mechanism of the immune response and has an important role in maintaining the hematopoietic cell niche in the bone marrow. During this process, the participation of molecules produced by innate immunity cells in response to a variety of pathogen-associated molecular patterns and damage-associated molecular patterns is observed. However, chronic inflammation is intrinsically associated with leukemogenesis, as it induces DNA damage in hematopoietic stem cells and contributes to the creation of the preleukemic clone. Several factors influence the malignant transformation within the hematopoietic microenvironment, with inflammasomes having a crucial role in this process, in addition to acting in the regulation of hematopoiesis and its homeostasis. Inflammasomes are intracellular multimeric complexes responsible for the maturation and secretion of the proinflammatory cytokines interleukin-1β and interleukin-18 and the cell death process via pyroptosis. Therefore, dysregulation of the activation of these complexes may be a factor in triggering several diseases, including leukemias, and this has been the subject of several studies in the area. In this review, we summarized the current knowledge on the relationship between inflammation and leukemogenesis, in particular, the role of inflammasomes in different types of leukemias, and we describe the potential therapeutic targets directed at inflammasomes in the leukemic context.